Compare Quest Diagnostics Inc (DGX) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs First Citizens BancShares Inc — how do they compare? Quest Diagnostics Inc trades at $236.29 (market cap $26.24B), while First Citizens BancShares Inc trades at $2,270.44 (market cap $25.26B). The key difference: Quest Diagnostics Inc and First Citizens BancShares Inc are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | FCNCA | |
|---|---|---|
Market Cap | $26.24B | $25.26B |
Sector | Health | Sector/Thematic |
52-Week High | $238.50 | $2.27K |
52-Week Low | $173.49 | $1.64K |
Enterprise Value | $32.00B | — |
Dividend Yield | 1.45% | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $236.04, down 0.61% on the day, as the stock consolidates near recent highs following strong Q2 2026 earnings. The company has delivered three consecutive quarterly earnings beats, with Q2 EPS of $3.12 exceeding expectations by 10.6%. Revenue growth accelerated to 10.2% year-over-year, supported by strong testing demand and strategic partnerships. Technical indicators show a bullish trend with the stock trading near pivot point resistance at $238.
The outlook remains positive with raised 2026 guidance and consistent dividend payments, though valuation multiples appear full at 25.2x P/E. Key risks include margin pressure from lower-margin contracts and rising project costs. Analyst consensus leans bullish with a $249.50 price target representing 5.7% upside potential from current levels.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a 12.19 P/E ratio, 25.23% net income margin, and consistent earnings beats in recent quarters. Recent business developments include expansion of commercial lending operations and strategic real estate acquisitions, supporting growth initiatives.
FCNCA presents a mixed outlook with strong earnings performance and reasonable valuation offset by cautious analyst sentiment. While technical indicators suggest continued upside potential, the 81.82% hold rating from analysts indicates concerns about valuation and deposit risks. Key opportunities include expanding commercial banking services, while risks center on net interest margin pressure and elevated uninsured deposits at 38.3%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
